Our findings primarily demonstrated that the circulating levels of GDF15 are higher in children with biopsy-proven MASLD compared to controls and increase with the progression of disease damage (i.e., MASH and fibrosis). The gene discussed is GDF15; the disease is metabolic dysfunction-associated steatotic liver disease.